Titan Pharma Common (TTNP) 5.25 $TTNP
Titan Pharmaceuticals Added to Russell 3000 Index
Marketwired - Mon Jun 27, 6:00AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 27, 2016) - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform, today announced that it has been added to the broad U.S. market Russell® 3000 Index and the small-cap Russell 2000® Index as part of Russell Investments' annual reconstitution of its stock indexes, effective at the opening of U.S. markets today.
TTNP: 5.25 (+0.03)
Hypothyroidism Therapeutics Pipeline Report H1 2016 - Review of Synthonics, Inc. & Titan Pharmaceuticals, Inc. - Research and Markets
BusinessWire - Thu Jun 23, 5:26AM CDT
Research and Markets has announced the addition of the "Hypothyroidism - Pipeline Review, H1 2016" report to their offering.
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine(R)
Marketwire Canada - Mon Jun 13, 6:00AM CDT
More Than 800 Health Care Providers Already Certified Under the Probuphine REMS Program
TTNP: 5.25 (+0.03)
FDA Approves Buprenorphine (Probuphine) Implant for Opioid Replacement Therapy
PR Newswire - Tue May 31, 7:30AM CDT
Probuphine - a first-of-its-kind buprenorphine implant for use by those dependent on opioids - has received approval from the FDA. The same drug has previously been available both as a pill form and as a film that dissolves under the tongue. Proponents of Probuphine, which was developed by Titan Pharmaceuticals and Braeburn Pharmaceuticals, say that the implant offers a host of advantages over other delivery methods.
TTNP: 5.25 (+0.03)
Braeburn Pharmaceuticals Announces FDA Approves Probuphine® (buprenorphine) Implant: The First Implant for Treatment of Opioid Dependence
PR Newswire - Thu May 26, 6:26PM CDT
Braeburn Pharmaceuticals announces that the U.S. Food & Drug Administration (FDA) approved Probuphine, the first implant for the maintenance treatment of opioid dependence in patients who have sustained clinical stability on low-to-moderate doses of buprenorphine, specifically 8 mg or less per day. Probuphine delivers buprenorphine continuously for up to six months and should be used as part of a complete treatment program to include counseling and psychosocial support.
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Announces FDA Approval of Probuphine(R) for the Treatment of Opioid Dependence
Marketwire Canada - Thu May 26, 3:53PM CDT
Buprenorphine Implant Is First Product for Six-Month, Long-Term Maintenance Treatment of Opioid Dependence; Titan to Receive $15 Million Milestone Payment
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Reports First Quarter 2016 Financial Results
Marketwired - Tue May 10, 6:00AM CDT
Titan Management Team to Host Conference Call Today at 4:15 P.M. EDT / 1:15 P.M. PDT
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2016 Financial Results
Marketwired - Wed May 04, 7:43PM CDT
Management Team to Host Conference Call May 10 at 4:15 p.m. EDT / 1:15 p.m. PDT
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Reports Full Year and Fourth Quarter 2015 Financial Results
Marketwired - Tue Mar 15, 6:00AM CDT
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery platform, today reported financial results for the full year and fourth quarter of 2015.
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals to Present at 28th Annual ROTH Conference
Marketwired - Tue Mar 08, 6:30AM CST
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery platform, announced today that Titan President and CEO Sunil Bhonsle will present at the 28th annual ROTH Conference on Monday, March 14 at 8:30 - 9:00 a.m. PT (11:30am - noon ET) at The Ritz-Carlton in Laguna Niguel, Calif.
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Receives Feedback From FDA on Ropinirole Implant Development Program for Parkinson's Disease
Marketwired - Mon Mar 07, 6:00AM CST
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that the U.S. Food and Drug Administration has provided written feedback on the initial development plan for its proprietary ropinirole hydrochloride (HCL) implant for Parkinson's disease. Based on the FDA's feedback on the development plan submitted in December 2015, Titan is proceeding with the required non-clinical studies to support the potential submission of an investigational new drug (IND) application in the fourth quarter of 2016, followed by the initial pharmacokinetic and proof-of-concept clinical study. Titan is pursuing a 505(b)(2) registration pathway for the product candidate.
TTNP: 5.25 (+0.03)
These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
ACCESSWIRE - Wed Feb 03, 12:50PM CST
LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
RPTP: 5.64 (-0.05), TTNP: 5.25 (+0.03), MNKD: 1.15 (+0.03), TLOG: 0.30 (unch)
Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction
PR Newswire - Tue Jan 12, 6:20PM CST
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) and partner Braeburn Pharmaceuticals today announced that the Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted 12 to 5 in favor of approving Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction, in stable patients receiving 8mg or less per day of buprenorphine. The Committee's vote followed presentation and discussion of data regarding Probuphine's efficacy, safety, and risk-benefit profile. The New Drug Application (NDA) for Probuphine was resubmitted to the FDA in August 2015, and accepted by the FDA in September 2015. A target agency action date has been set for February 27, 2016.
TTNP: 5.25 (+0.03)
Trading of Titan Pharmaceuticals Stock Halted Today
Marketwired - Tue Jan 12, 6:05AM CST
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that Nasdaq has halted trading in its common stock. The U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting today to discuss the New Drug Application (NDA) for Probuphine(R) for the maintenance treatment of opioid addiction.
TTNP: 5.25 (+0.03)
Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors
GlobeNewswire - Fri Jan 08, 7:10AM CST
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election of Marc Rubin, M.D. as Chairman of the Board of Directors. Dr. Rubin, who has been serving as lead independent Director, succeeds James C. Czirr, who helped found the Company in 2000 and has served as Executive Chairman for the past seven years. Mr. Czirr will continue to serve as a Director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and Board experience in the development and commercialization of pharmaceuticals.
CRIS: 1.62 (+0.07), TTNP: 5.25 (+0.03), GALT: 1.51 (-0.02)
Titan Pharmaceuticals Added to Russell 3000 Index
Marketwired - Mon Jun 27, 6:00AM CDT
SOUTH SAN FRANCISCO, CA--(Marketwired - Jun 27, 2016) - Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura™ long-term, continuous drug delivery platform, today announced that it has been added to the broad U.S. market Russell® 3000 Index and the small-cap Russell 2000® Index as part of Russell Investments' annual reconstitution of its stock indexes, effective at the opening of U.S. markets today.
TTNP: 5.25 (+0.03)
Hypothyroidism Therapeutics Pipeline Report H1 2016 - Review of Synthonics, Inc. & Titan Pharmaceuticals, Inc. - Research and Markets
BusinessWire - Thu Jun 23, 5:26AM CDT
Research and Markets has announced the addition of the "Hypothyroidism - Pipeline Review, H1 2016" report to their offering.
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Receives $15 Million Milestone Payment Following FDA Approval of Probuphine(R)
Marketwire Canada - Mon Jun 13, 6:00AM CDT
More Than 800 Health Care Providers Already Certified Under the Probuphine REMS Program
TTNP: 5.25 (+0.03)
FDA Approves Buprenorphine (Probuphine) Implant for Opioid Replacement Therapy
PR Newswire - Tue May 31, 7:30AM CDT
Probuphine - a first-of-its-kind buprenorphine implant for use by those dependent on opioids - has received approval from the FDA. The same drug has previously been available both as a pill form and as a film that dissolves under the tongue. Proponents of Probuphine, which was developed by Titan Pharmaceuticals and Braeburn Pharmaceuticals, say that the implant offers a host of advantages over other delivery methods.
TTNP: 5.25 (+0.03)
Braeburn Pharmaceuticals Announces FDA Approves Probuphine® (buprenorphine) Implant: The First Implant for Treatment of Opioid Dependence
PR Newswire - Thu May 26, 6:26PM CDT
Braeburn Pharmaceuticals announces that the U.S. Food & Drug Administration (FDA) approved Probuphine, the first implant for the maintenance treatment of opioid dependence in patients who have sustained clinical stability on low-to-moderate doses of buprenorphine, specifically 8 mg or less per day. Probuphine delivers buprenorphine continuously for up to six months and should be used as part of a complete treatment program to include counseling and psychosocial support.
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Announces FDA Approval of Probuphine(R) for the Treatment of Opioid Dependence
Marketwire Canada - Thu May 26, 3:53PM CDT
Buprenorphine Implant Is First Product for Six-Month, Long-Term Maintenance Treatment of Opioid Dependence; Titan to Receive $15 Million Milestone Payment
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Reports First Quarter 2016 Financial Results
Marketwired - Tue May 10, 6:00AM CDT
Titan Management Team to Host Conference Call Today at 4:15 P.M. EDT / 1:15 P.M. PDT
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Schedules Conference Call to Review First Quarter 2016 Financial Results
Marketwired - Wed May 04, 7:43PM CDT
Management Team to Host Conference Call May 10 at 4:15 p.m. EDT / 1:15 p.m. PDT
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Reports Full Year and Fourth Quarter 2015 Financial Results
Marketwired - Tue Mar 15, 6:00AM CDT
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery platform, today reported financial results for the full year and fourth quarter of 2015.
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals to Present at 28th Annual ROTH Conference
Marketwired - Tue Mar 08, 6:30AM CST
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of select chronic diseases utilizing its ProNeura(TM) long-term, continuous drug delivery platform, announced today that Titan President and CEO Sunil Bhonsle will present at the 28th annual ROTH Conference on Monday, March 14 at 8:30 - 9:00 a.m. PT (11:30am - noon ET) at The Ritz-Carlton in Laguna Niguel, Calif.
TTNP: 5.25 (+0.03)
Titan Pharmaceuticals Receives Feedback From FDA on Ropinirole Implant Development Program for Parkinson's Disease
Marketwired - Mon Mar 07, 6:00AM CST
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that the U.S. Food and Drug Administration has provided written feedback on the initial development plan for its proprietary ropinirole hydrochloride (HCL) implant for Parkinson's disease. Based on the FDA's feedback on the development plan submitted in December 2015, Titan is proceeding with the required non-clinical studies to support the potential submission of an investigational new drug (IND) application in the fourth quarter of 2016, followed by the initial pharmacokinetic and proof-of-concept clinical study. Titan is pursuing a 505(b)(2) registration pathway for the product candidate.
TTNP: 5.25 (+0.03)
These Biotech Companies are Helping Turn Around the Sector for Major Gains in 2016
ACCESSWIRE - Wed Feb 03, 12:50PM CST
LAS VEGAS, NV / ACCESSWIRE / February 3, 2016 / The most notable of the pack is Propanc Health Group Corporation (PPCH), which is an exciting, young company within the sector. Propanc, whose focus is the development of new and proprietary treatments for cancer patients suffering from pancreatic, ovarian and colorectal cancers, recently announced the Company received a further $525,000 tranche from an institutional investor in order to progress their lead product, PRP, towards human trials. PPCH has already grabbed the attention of more than a few investors thanks to the Company's substantial growth in 2015 and expected growth in 2016.
RPTP: 5.64 (-0.05), TTNP: 5.25 (+0.03), MNKD: 1.15 (+0.03), TLOG: 0.30 (unch)
Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction
PR Newswire - Tue Jan 12, 6:20PM CST
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) and partner Braeburn Pharmaceuticals today announced that the Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted 12 to 5 in favor of approving Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction, in stable patients receiving 8mg or less per day of buprenorphine. The Committee's vote followed presentation and discussion of data regarding Probuphine's efficacy, safety, and risk-benefit profile. The New Drug Application (NDA) for Probuphine was resubmitted to the FDA in August 2015, and accepted by the FDA in September 2015. A target agency action date has been set for February 27, 2016.
TTNP: 5.25 (+0.03)
Trading of Titan Pharmaceuticals Stock Halted Today
Marketwired - Tue Jan 12, 6:05AM CST
Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) announced today that Nasdaq has halted trading in its common stock. The U.S. Food and Drug Administration's (FDA) Psychopharmacologic Drugs Advisory Committee (PDAC) is meeting today to discuss the New Drug Application (NDA) for Probuphine(R) for the maintenance treatment of opioid addiction.
TTNP: 5.25 (+0.03)
Galectin Therapeutics Appoints Dr. Marc Rubin Chairman of the Board of Directors
GlobeNewswire - Fri Jan 08, 7:10AM CST
Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announces the election of Marc Rubin, M.D. as Chairman of the Board of Directors. Dr. Rubin, who has been serving as lead independent Director, succeeds James C. Czirr, who helped found the Company in 2000 and has served as Executive Chairman for the past seven years. Mr. Czirr will continue to serve as a Director. Dr. Rubin is a leading bioscience industry executive with more than 25 years of senior management and Board experience in the development and commercialization of pharmaceuticals.
CRIS: 1.62 (+0.07), TTNP: 5.25 (+0.03), GALT: 1.51 (-0.02)
